Stealth BioTherapeutics Corp - ADR

NASDAQ:MITO   3:54:21 PM EDT
0.22
-0.01 (-4.19%)
Products

Stealth BioTherapeutics Receives Orphan Drug Designation From FDA For Elamipretide For Treatment Of Duchenne Muscular Dystrophy

Published: 05/12/2022 11:56 GMT
Stealth BioTherapeutics Corp - ADR (MITO) - Stealth Biotherapeutics Receives Orphan Drug Designation From FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophy.
Stealth Biotherapeutics Receives Orphan Drug Designation From FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophy.